Singular Genomics regains compliance with Nasdaq minimum bid price requirement

Singular Genomics Systems received formal notice from the Nasdaq Stock Market that the Company has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. As previously disclosed, on July 17, Singular Genomics received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq’s listing requirements because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days. As determined by Nasdaq, the closing bid price of the Company’s common stock was at $1.00 per share or greater for 11 consecutive days from June 26 to July 11. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed.